The state of Texas currently has 3 active clinical trials seeking participants for Hepatitis C research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Recruiting
Hepatitis C Virus (HCV) infection is a global health problem. HCV mainly affects liver cells and causes the liver to become inflamed and damaged. This study will evaluate how safe and effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and adolescent participants with acute HCV infection. GLE/PIB is an approved drug for the treatment of chronic HCV. Around 283 participants at least 12 years of age with acute HCV Infection will be enrolled in approximately 70 sites worldwide. Participants... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/11/2024
Locations: Liver Associates of Texas, P.A /ID# 229775, Houston, Texas
Conditions: Hepatitis C Virus (HCV)
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: Liver Center of Texas, Dallas, Texas +1 locations
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
The Hepatitis C Transplant Collaborative
Recruiting
In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2023
Locations: Baylor Scott & White Health Research Institute, Dallas, Texas
Conditions: Transplant; Failure, Heart, Hepatitis C